ARCHIVES

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

ODAC Recommends Iressa Approval As Third-Line Lung Cancer Treatment

September 27, 2002

Study Finds Trial Results Reliable At Three Years

July 29, 2005

Report Tells NCI to Increase Funding for SPOREs.

June 30, 2006

In Brief: Goldman Named Director, Albert Einstein Cancer Center; Wiernik Resumes Post

October 20, 1995

GM Corp, to Reimburse Marrow Transplants for Breast Cancer

March 15, 1996

Trial Links Potential Biomarkers To Drugs For Lung Cancer, To Help Target Therapies

April 30, 2010